Australian ovarian cancer survival up, but "early detection still key need"
This article was originally published in Clinica
The development of an effective early detection test remains the top priority for future research into ovarian cancer, Australian experts have said, following yesterday's publication of a report appraising the latest incidence and care outcomes data.
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.